<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136143">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01858480</url>
  </required_header>
  <id_info>
    <org_study_id>RC 04C 010</org_study_id>
    <nct_id>NCT01858480</nct_id>
  </id_info>
  <brief_title>Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Study To Evaluate D-Ribose For The Treatment Of Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RiboCor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RiboCor, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and to determine the efficacy of D-ribose for the treatment of
      congestive heart failure (CHF) in subjects who have been stabilized following
      hospitalization with acute decompensation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center study of
      D-ribose administered via peripheral intravenous line for 24 hours to stabilized
      hospitalized patients following standard of care treatment for acute decompensation of CHF,
      followed by oral dosing of D-ribose three times a daily through the remainder of the
      inpatient hospital stay and outpatient period of 3 months.  Subjects will complete
      Pretreatment Screening procedures only after the Investigator has established that they have
      met the pre-specified criteria for stabilization of heart failure, and be randomized to
      treatment no more than 7 days after admission to the hospital.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF), measured by transthoracic 2-D echocardiography with contrast</measure>
    <time_frame>LVEF (by 2-D echocardiography): Change from Baseline to Month 3</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Efficacy Analyses:  The primary efficacy analysis will be performed by comparison of active versus placebo treatment groups.  Summary statistics, including means and standard deviations, will be provided.  Analysis of covariance will be used to analyze the on-treatment LVEF scores with the pre-treatment LVEF score serving as the covariate.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>D-ribose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>D-ribose administered via peripheral intravenous for 24 hours followed by oral D ribose dosing for 3 months versus placebo in subjects with CHF who have been stabilized following hospitalization for acute decompensation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dosage form designed to mock active.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-ribose</intervention_name>
    <description>D-ribose powder for oral solution and D-ribose for injection.</description>
    <arm_group_label>D-ribose</arm_group_label>
    <other_name>ribose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo dosage form designed to mock active.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent and Health Insurance Portability and Accountability Act
             authorization, as applicable;

          -  symptomatic heart failure (NYHA Class II, III or IV) ≥ 30 days prior to current acute
             decompensation episode;

          -  ≥2 of the following signs of acute decompensation: jugular venous distension, rales,
             dyspnea, and ≥ 1+ pedal edema;

          -  admitted to the hospital ≤ 36 hours after initial evaluation;

          -  discontinued from IV inotropic support ≥ 48 hours prior to Screening;

          -  initiated Screening when subject has met the following criteria for stabilization:

          -  exacerbating factors addressed;

          -  near optimal volume status;

          -  transition from IV to oral diuretic completed;

          -  near optimal pharmacologic therapy achieved or intolerance documented;

          -  completed Screening procedures and been randomized to treatment ≤ 7 days after
             hospital admission;

          -  LVEF ≤ 35% ≤ 12 months prior to Screening.

          -  if female, ≥ 2 years post-menopausal, surgically sterile, or practicing effective
             contraception;

          -  if female, non-lactating, and if of child-bearing potential, has negative pregnancy
             test result at Screening;

          -  willing to abstain from ribose-containing products during study.

        Exclusion Criteria:

          -  significant medical condition(s) which, in Investigator's judgment, could compromise
             subject's welfare or confound study results;

          -  significant hepatic, renal, or hematologic disorder/dysfunction beyond that expected
             from CHF alone;

          -  Creatinine Clearance &lt;30.0 mL/min at Screening;

          -  serum potassium level &lt;3.5 milliequivalent per liter or &gt;5.7 milliequivalent per
             liter, or a serum sodium level &lt;130 milliequivalent per liter at Screening;

          -  systolic arterial blood pressure &lt;90 mm Hg at Screening;

          -  received ultrafiltration during current admission;

          -  cardiac surgery ≤ 60 days prior to Screening, except for percutaneous intervention;

          -  planned revascularization procedures, electrophysiologic device or cardiac mechanical
             support implantation, cardiac transplantation, or other cardiac surgery ≤ 90 days
             after study enrollment;

          -  functional mitral valve regurgitation &gt; moderate severity;

          -  aortic regurgitation of at least moderate severity;

          -  hemodynamically significant primary cardiac valvular disease;

          -  myocardial infarction ≤ 30 days prior to Screening;

          -  Acute Coronary Syndrome ≤ 30 days prior to Screening;

          -  known or suspected right-to-left, bi-directional, or transient right-to-left cardiac
             shunt;

          -  sustained ventricular tachycardia or ventricular fibrillation ≤ 30 days prior to
             Screening, unless automatic implantable cardioverter defibrillator is present;

          -  atrial fibrillation within the past year;

          -  CHF related to tachyarrhythmias or bradyarrhythmias;

          -  CHF due to uncorrected thyroid disease, active myocarditis, or known amyloid
             cardiomyopathy;

          -  angina at rest or with slight exertion and/or unstable angina;

          -  diagnosed with hypertrophic cardiomyopathy;

          -  cerebrovascular accident ≤ 6 months prior to Screening;

          -  cardiogenic shock at any time from initial evaluation to randomization;

          -  on cardiac mechanical support;

          -  biventricular pacer placement ≤ 60 days prior to Screening or needed pacemaker
             placement during the current admission;

          -  refractory, end-stage heart failure;

          -  type I or type II diabetes;

          -  history of pancreatitis;

          -  current systemic infection;

          -  urinary tract obstruction;

          -  morbidly obese (weight &gt; 159 kg [350 lbs] or BMI &gt;42 kg/m2);

          -  active malignancy at Screening.  [Treatment for basal cell or stage 1 squamous cell
             carcinoma, or cervical carcinoma in situ allowed];

          -  terminally ill or has moribund condition;

          -  history of irritable bowel syndrome, inflammatory bowel disease, ischemic colitis,
             vascular intestinal atherosclerosis, previous bowel resection, impaction, or similar
             gastrointestinal conditions;

          -  currently taking Kayexalate® (sodium polystyrene sulfonate);

          -  allergic reaction to Optison™ or Definity® or any of their components.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilson S Colucci, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kimberly O'Malie</last_name>
    <phone>(480) 397-1732</phone>
    <email>Kimberly.OMalia@integrium.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Wiggins, MS</last_name>
      <phone>562-933-8759</phone>
    </contact>
    <investigator>
      <last_name>Marvin Appel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novo Research, Inc.</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95350</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiffini Clark</last_name>
      <phone>209-549-9538</phone>
    </contact>
    <investigator>
      <last_name>Lyn Raible, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Olive View-UCLA- Medical Center</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvador Hernadez</last_name>
      <phone>818-364-4287</phone>
    </contact>
    <investigator>
      <last_name>Sheba Meymandi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Beckmann</last_name>
      <phone>310-222-3560</phone>
    </contact>
    <investigator>
      <last_name>Ronald Oudiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeast Regional Research Group</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Hutchinson, CCRC</last_name>
      <phone>702-321-0495</phone>
    </contact>
    <investigator>
      <last_name>Zulfiquar Bhatti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercer University - Mercer Medicine</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marnie Hill, BS, CCRC</last_name>
      <phone>478-301-5846</phone>
    </contact>
    <investigator>
      <last_name>Jalal K. Ghali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Consultants PC</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry Adair</last_name>
      <phone>765-254-4761</phone>
    </contact>
    <investigator>
      <last_name>Wayne Gray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cynthia Larew, BSN</last_name>
      <phone>319-356-7953</phone>
    </contact>
    <investigator>
      <last_name>KellyAnn Light-McGroary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedPharmics</name>
      <address>
        <city>Kenner</city>
        <state>Louisiana</state>
        <zip>70065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Slocum, LPN</last_name>
      <phone>504-265-9951</phone>
    </contact>
    <investigator>
      <last_name>Robert J Jeanfreau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Androscoggin Cardiology Associates / dba Maine Research Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Dunham</last_name>
      <phone>207-330-7868</phone>
    </contact>
    <contact_backup>
      <last_name>Marissa Tardif</last_name>
      <phone>207-782-9835</phone>
    </contact_backup>
    <investigator>
      <last_name>Robert J Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joanne Marshall</last_name>
      <phone>410-328-8790</phone>
    </contact>
    <investigator>
      <last_name>Stephen Gottlieb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genesys Regional Medical Ctr</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Huckabone, RN</last_name>
      <phone>810-606-5377</phone>
    </contact>
    <investigator>
      <last_name>Thomas Vanhecke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Medicine and Dentistry of New Jersey</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zoha Shir, RN, BSN, MSN</last_name>
      <phone>973-972-6794</phone>
    </contact>
    <investigator>
      <last_name>Pallavi Solanki (Klapolz), MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bikash Saha</last_name>
      <phone>201-541-6375</phone>
    </contact>
    <investigator>
      <last_name>Stephen Angeli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Marks, RN</last_name>
      <phone>212-305-1368</phone>
    </contact>
    <investigator>
      <last_name>Paul Christian Schulze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Intravaia, RN, CCRC II</last_name>
      <phone>631-444-3626</phone>
    </contact>
    <investigator>
      <last_name>Hal Skopicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Foundation for Cardiovascular Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bev Hudson</last_name>
      <phone>405-608-1282</phone>
    </contact>
    <investigator>
      <last_name>Philip Adamson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Drexel University College of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Colleen Poisker, RN, BSN</last_name>
      <phone>215-762-8512</phone>
    </contact>
    <investigator>
      <last_name>Howard Eisen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Clinical Research Institute</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cynthia Allbritton, RN</last_name>
      <phone>901-226-1688</phone>
    </contact>
    <investigator>
      <last_name>Frank McGrew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michael DeBakey VAMC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariana VBolos, MBBCh</last_name>
      <phone>713-794-8922</phone>
    </contact>
    <investigator>
      <last_name>Tony Ma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Fernando</last_name>
      <phone>416-864-6060</phone>
    </contact>
    <investigator>
      <last_name>Gorgon Moe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital / MUHC</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Boudreault</last_name>
      <phone>514-934-1934</phone>
    </contact>
    <investigator>
      <last_name>Thao Huynh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chum Hotel Dieu</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Vallieres</last_name>
      <phone>514-890-8000</phone>
    </contact>
    <investigator>
      <last_name>Samer Mansour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie Lapointe, RN, PhD</last_name>
      <phone>514-340-8222</phone>
    </contact>
    <investigator>
      <last_name>Richard Sheppard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>August 27, 2013</lastchanged_date>
  <firstreceived_date>May 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CHF</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
